INDV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

306.22M

+2.76%

0.678

+112.61%

269.53M

+1.33%

0.650

+58.54%

281.67M

-6.73%

0.707

+38.56%

Estimates Revision

The market is revising Upward the revenue expectations for Indivior PLC (INDV) for FY2025, with the revenue forecasts being adjusted by 9.91% over the past three months. During the same period, the stock price has changed by 47.66%.

Revenue Estimates for FY2025

Revise Upward

+9.91%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+34.43%

In Past 3 Month

Stock Price

Go Up

+47.66%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38.67 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

35.00

Averages

38.67

High

41.00

Current: 0.000

Low

35.00

Averages

38.67

High

41.00

Morgan Stanley

Overweight

maintain

$28 -> $36

2025-12-03

Reason

Morgan Stanley

Price Target

$28 -> $36

2025-12-03

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Indivior to $36 from $28 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.

Northland

Outperform

upgrade

$30 -> $40

2025-10-31

Reason

Northland

Price Target

$30 -> $40

2025-10-31

upgrade

Outperform

Reason

Northland raised the firm's price target on Indivior to $40 from $30 and keeps an Outperform rating on the shares. The firm's upward revision reflects confidence in Sublocade's prospects, combined with Indivior's cost containment initiatives, the analyst tells investors.

Craig-Hallum

Buy

maintain

$34 -> $41

2025-10-31

Reason

Craig-Hallum

Price Target

$34 -> $41

2025-10-31

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Indivior to $41 from $34 and keeps a Buy rating on the shares. The firm cites the company's Q3 massive beat, delivering revenue of $314M, beating Street estimates of $261.9M, with broad-based strength from both Sublocade and Suboxone.

Piper Sandler

NULL -> Overweight

upgrade

$27 -> $41

2025-10-31

Reason

Piper Sandler

Price Target

$27 -> $41

2025-10-31

upgrade

NULL -> Overweight

Reason

Piper Sandler raised the firm's price target on Indivior to $41 from $27 and keeps an Overweight rating on the shares. The firm notes Indivior reported Q3 2025 diluted non-GAAP earnings per share of 72c on revenue of $314M, compared to Street estimates of 41c and $262M, respectively. Management is now guiding to Sublocade worldwide sales of $825M-$845M, up from the previous range of $765M-$785M, and now implying annual growth of about 10% at the midpoint.

H.C. Wainwright

Brandon Folkes

maintain

$28 -> $35

2025-10-30

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$28 -> $35

2025-10-30

maintain

Reason

H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Indivior to $35 from $28 and keeps a Buy rating on the shares. The company reported a strong Q3 that exceeded expectations across all key metrics and validated the firm's positive call on the stock into the quarter, the analyst tells investors in a research note. The firm added that its revised target may still prove conservative, as it implies just 7.4x 2026 EV/EBITDA, compared to the peer group average of about 9.8x, suggesting meaningful re-rating potential as execution continues.

H.C. Wainwright

Brandon Folkes

Buy

initiated

$27

2025-08-06

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$27

2025-08-06

initiated

Buy

Reason

H.C. Wainwright analyst Brandon Folkes initiated coverage of Indivior with a Buy rating and $27 price target. The firm sees a favorable risk/reward at current share levels, saying the durability of Sublocade revenue in the growing long-acting injectable market for opioid use disorder is underappreciated. In addition, Indivior's operational focus could drive meaningful cost reduction efforts in non-core areas of the company, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Indivior PLC (INDV.O) is 12.72, compared to its 5-year average forward P/E of 12.59. For a more detailed relative valuation and DCF analysis to assess Indivior PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.59

Current PE

12.72

Overvalued PE

15.93

Undervalued PE

9.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

6.60

Current EV/EBITDA

8.93

Overvalued EV/EBITDA

8.38

Undervalued EV/EBITDA

4.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.27

Current PS

3.88

Overvalued PS

2.94

Undervalued PS

1.60

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

INDV News & Events

Events Timeline

No data

News

6.5

2025-12-28NASDAQ.COM

Stonepine Capital Reduces Indivior Stake by 250,000 Shares, Valuation Drops by $2.75 Million

6.5

2025-12-28Fool

Stonepine Capital Reduces Indivior Stake by $2.75 Million

8.5

2025-12-22PRnewswire

Indivior PLC Added to S&P SmallCap 600 Index, Enhancing Market Presence

People Also Watch

Frequently Asked Questions

What is Indivior PLC (INDV) stock price today?

The current price of INDV is 35.66 USD — it has increased 0.42 % in the last trading day.

What is Indivior PLC (INDV)'s business?

Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.

What is the price predicton of INDV Stock?

What is Indivior PLC (INDV)'s revenue for the last quarter?

Indivior PLC revenue for the last quarter amounts to 314.00M USD, increased 2.28 % YoY.

What is Indivior PLC (INDV)'s earnings per share (EPS) for the last quarter?

Indivior PLC. EPS for the last quarter amounts to 0.33 USD, increased 94.12 % YoY.

What changes have occurred in the market's expectations for Indivior PLC (INDV)'s fundamentals?

How many employees does Indivior PLC (INDV). have?

Indivior PLC (INDV) has 1030 emplpoyees as of January 09 2026.

What is Indivior PLC (INDV) market cap?

Today INDV has the market capitalization of 4.44B USD.